Bank of Montreal Can Raises Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Bank of Montreal Can boosted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 141.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 160,138 shares of the biopharmaceutical company's stock after purchasing an additional 93,702 shares during the quarter. Bank of Montreal Can owned approximately 0.33% of Theravance Biopharma worth $1,414,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TBPH. XTX Topco Ltd purchased a new position in Theravance Biopharma during the second quarter valued at $129,000. Hsbc Holdings PLC purchased a new position in Theravance Biopharma in the 2nd quarter valued at about $108,000. Dimensional Fund Advisors LP boosted its holdings in Theravance Biopharma by 38.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company's stock worth $2,800,000 after buying an additional 91,679 shares during the last quarter. American Century Companies Inc. boosted its holdings in Theravance Biopharma by 11.7% in the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company's stock worth $489,000 after buying an additional 6,026 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Theravance Biopharma during the 2nd quarter worth approximately $286,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of the stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares in the company, valued at $74,186,970. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, major shareholder Eli Samaha acquired 999,800 shares of the business's stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the transaction, the insider now owns 9,511,150 shares of the company's stock, valued at $74,186,970. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now owns 335,965 shares of the company's stock, valued at approximately $3,023,685. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.90% of the stock is owned by insiders.

Analyst Ratings Changes

TBPH has been the topic of a number of research analyst reports. TD Cowen lowered their price target on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a research note on Tuesday, August 6th. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th. StockNews.com lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, August 10th. Leerink Partners downgraded Theravance Biopharma from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, Leerink Partnrs cut shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $13.75.

Theravance Biopharma Price Performance

TBPH stock remained flat at $8.10 during midday trading on Friday. The company's stock had a trading volume of 239,152 shares, compared to its average volume of 211,988. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $11.71. The company's fifty day simple moving average is $8.32 and its 200-day simple moving average is $8.81. The stock has a market capitalization of $393.93 million, a PE ratio of -9.42 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The company had revenue of $14.26 million for the quarter, compared to analysts' expectations of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same period last year, the business earned ($0.28) EPS. Equities research analysts forecast that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.